Group B Streptococcus as a Urinary Pathogen

Understanding GBS as a Urinary Pathogen

The Centers for Disease Control and Prevention recommends that any concentration of GBS in urine during pregnancy mandates immediate treatment and intrapartum IV antibiotic prophylaxis during labor, regardless of symptoms or colony count 1, 2, 5, 6
GBS bacteriuria is a marker for heavy genital tract colonization and significantly increases the risk of early-onset neonatal disease by more than 25-fold, according to the American College of Obstetricians and Gynecologists 1, 6

The American College of Obstetricians and Gynecologists states that women with GBS bacteriuria at any point during pregnancy should not undergo vaginal-rectal screening at 35-37 weeks—they are presumed colonized and automatically qualify for intrapartum prophylaxis 2, 5
Treating the UTI during pregnancy does NOT eliminate GBS colonization; recolonization after oral antibiotics is typical, which is why intrapartum IV prophylaxis remains mandatory, as recommended by the Centers for Disease Control and Prevention 2, 5, 6
Intrapartum prophylaxis administered ≥4 hours before delivery is 78% effective in preventing early-onset neonatal GBS disease, according to the American Academy of Pediatrics 2, 5

The Infectious Diseases Society of America recommends that treatment should be provided for symptomatic UTI or in patients with underlying urinary tract abnormalities; asymptomatic bacteriuria with GBS should NOT be treated in nonpregnant patients 4

The World Health Organization notes that all GBS isolates worldwide remain universally susceptible to penicillin and ampicillin—no penicillin-resistant GBS has ever been documented 5
The Centers for Disease Control and Prevention reports that GBS shows high resistance to tetracycline (81.6-88.46%) and co-trimoxazole (68.9%) 5
The European Centre for Disease Prevention and Control states that erythromycin resistance ranges from 7-25%, and clindamycin resistance from 3-77.34%, with significant geographic variation 5